| Not Yet Recruiting | Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-n NCT05522491 | Hebei Medical University Fourth Hospital | Phase 2 |
| Recruiting | NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry fo NCT07489378 | National Cancer Institute (NCI) | — |
| Recruiting | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors NCT07517198 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | DXP-106 in Solid Tumor Patients. NCT07532018 | Singlomics Biopharmaceuticals Zhuhai Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects NCT07446153 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Pilot Study of Freeze-Dried Miracle Fruit (MiraBurst) on Participants Receiving Cancer Treatment NCT07419581 | Case Comprehensive Cancer Center | N/A |
| Recruiting | Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology NCT07464457 | Priv.-Doz. Dr. med. Philipp Lenz | N/A |
| Recruiting | Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors NCT07487597 | TCRCure Biopharma Ltd. | EARLY_Phase 1 |
| Not Yet Recruiting | 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors NCT07404332 | Mohammed Milhem | Phase 1 |
| Recruiting | A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tum NCT07229638 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas NCT07222631 | University of California, San Diego | Phase 1 / Phase 2 |
| Recruiting | Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss NCT07382544 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors NCT07466160 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Atamparib in Patients With Advanced Solid Tumors NCT07374419 | Nerviano Medical Sciences (Shanghai) Ltd. | Phase 1 / Phase 2 |
| Recruiting | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer NCT07432295 | I-Mab Biopharma US Limited | Phase 2 |
| Not Yet Recruiting | TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors NCT07342738 | Sun Yat-sen University | EARLY_Phase 1 |
| Active Not Recruiting | Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET NCT07450560 | Shuanghu Yuan | — |
| Not Yet Recruiting | UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations NCT06895681 | University of California, San Francisco | — |
| Recruiting | This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Soli NCT07327632 | Innovent Biologics Technology Limited (Shanghai R&D Center) | EARLY_Phase 1 |
| Recruiting | DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Ca NCT07225088 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy NCT06579469 | St. Jude Children's Research Hospital | — |
| Recruiting | FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumor NCT06809114 | Axcynsis Therapeutics Pte Ltd | Phase 1 |
| Not Yet Recruiting | Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced NCT07086768 | Lei Zheng | Phase 1 |
| Recruiting | A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor NCT07275242 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Recruiting | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors NCT07358806 | Oscotec Inc. | Phase 1 |
| Recruiting | Ex Vivo Expansion (ACT-X) NCT07137312 | Mayo Clinic | — |
| Not Yet Recruiting | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Car NCT07100925 | Ankyra Therapeutics, Inc | Phase 1 |
| Recruiting | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and NCT07232524 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With An NCT07245901 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 1 / Phase 2 |
| Recruiting | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. NCT07165132 | RayzeBio, Inc. | Phase 1 |
| Recruiting | A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors NCT07229586 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study of ZGGS34 in Participants With Advanced Solid Tumors NCT07258121 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors NCT07300150 | PAQ Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid NCT07232420 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor NCT07140393 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in P NCT06441331 | ITM Solucin GmbH | Phase 1 |
| Recruiting | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations NCT07109726 | Terremoto Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT07003321 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Not Yet Recruiting | OH2 Administered by Intratumoral Injection NCT05954091 | Binhui Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors NCT07151040 | One-carbon Therapeutics AB | Phase 1 / Phase 2 |
| Withdrawn | IN10018 Combination Therapy in Previously-treated Solid Tumors NCT05982522 | InxMed (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of HDM2020 in Patients With Advanced Solid Tumors NCT07098052 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) i NCT06398418 | Rise Therapeutics LLC | Phase 1 |
| Recruiting | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid NCT07056556 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204 | Astellas Pharma Inc | Phase 1 |
| Recruiting | A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors NCT07069062 | Sichuan Huiyu Pharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Imaging of Solid Tumors Using 18F-TRX NCT06942104 | Rahul Aggarwal | Phase 1 |
| Recruiting | PET [89Zr]DFO-starPEG in Solid Tumors NCT06894745 | Robert Flavell, MD, PhD | Phase 1 |
| Not Yet Recruiting | A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Thera NCT06949761 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Implementation of an Oral Chemotherapy Adherence Intervention NCT06989489 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Terminated | Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors NCT07108140 | TCRCure Biopharma Ltd. | EARLY_Phase 1 |
| Recruiting | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tu NCT06954077 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Meta NCT06932952 | Byondis B.V. | Phase 1 |
| Recruiting | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Pa NCT06975293 | STORM Therapeutics LTD | Phase 1 / Phase 2 |
| Recruiting | A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors NCT06952010 | Exelixis | Phase 1 |
| Recruiting | Study on GD2 Positive Solid Tumors by 4SCAR-GD2 NCT02992210 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Not Yet Recruiting | CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors NCT06939270 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC NCT06966583 | Sichuan University | Phase 1 |
| Recruiting | A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors NCT06816108 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031 | Guangzhou JOYO Pharma Co., Ltd | Phase 2 |
| Recruiting | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With NCT06810544 | Tango Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Study of BHV-1530 in Advanced Solid Tumors NCT06874335 | Biohaven Therapeutics Ltd. | Phase 1 |
| Recruiting | PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor NCT06883149 | Chinese PLA General Hospital | Phase 1 |
| Recruiting | Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignanci NCT06801002 | Jabez Bioscience, Inc | Phase 1 |
| Recruiting | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diag NCT07107633 | Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd. | Phase 2 |
| Not Yet Recruiting | Clinical Study of Tumor Polypeptide DC-CTL in the Treatment of Solid Tumors NCT06524024 | Zhengzhou Revo-Gene Technology Co., LTD | N/A |
| Recruiting | Brodalumab in the Treatment of Immune-Related Adverse Events NCT06673329 | Brian Henick, MD | Phase 1 |
| Recruiting | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors NCT06911333 | Avelos Therapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors NCT06578624 | Lamassu Bio Inc | Phase 1 / Phase 2 |
| Recruiting | Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors NCT06563375 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastat NCT06873659 | Qurgen Inc. | Phase 1 |
| Recruiting | Concurrent Azeliragon With Craniospinal Irradiation NCT06724926 | NYU Langone Health | Phase 1 |
| Recruiting | A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors NCT06718621 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Withdrawn | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells NCT07071909 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Terminated | A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advan NCT06337630 | Institut Curie | Phase 1 |
| Not Yet Recruiting | MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors NCT06719856 | Peking University Cancer Hospital & Institute | — |
| Not Yet Recruiting | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tum NCT06755242 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors NCT06720298 | Peking University Cancer Hospital & Institute | — |
| Recruiting | A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies NCT06971523 | CytosinLab Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663 | RenJi Hospital | Phase 2 / Phase 3 |
| Recruiting | A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors NCT06797336 | PAQ Therapeutics, Inc. | Phase 1 |
| Recruiting | Ixovex-1 Single Agent and Combination Therapy NCT06549946 | Psivac Ltd | Phase 1 / Phase 2 |
| Recruiting | Study of BM230 in Patients With Advanced Solid Tumors NCT06644300 | Suzhou Biomissile Pharmaceuticals Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in C NCT06710847 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Recruiting | PET-imaging of Two Vartumabs in Patients With Solid Tumors NCT06645808 | Var2 Pharmaceuticals | EARLY_Phase 1 |
| Recruiting | 68Ga-MY6349 PET/CT in Solid Tumors NCT07046702 | The First Affiliated Hospital of Xiamen University | — |
| Recruiting | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. NCT06603844 | Corbus Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Recruiting | CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors NCT06646952 | Hua Zhu | — |
| Not Yet Recruiting | PICC-ports Versus Chest - Ports for Long Term Chemotherapy Deliverance in Oncology Patients NCT06541301 | European Institute of Oncology | N/A |
| Recruiting | A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine NCT06712680 | Sichuan Huiyu Pharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy NCT06689800 | Washington University School of Medicine | N/A |
| Recruiting | A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in NCT06619587 | Genentech, Inc. | Phase 1 |
| Recruiting | Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion NCT06739395 | Tianjin Medical University Second Hospital | Phase 2 |
| Recruiting | Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Meta NCT06576037 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT06609187 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT06667960 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Recruiting | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations NCT06669117 | Pierre Fabre Medicament | Phase 1 / Phase 2 |
| Recruiting | An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours NCT06695689 | Suzhou BlueHorse Therapeutics Co., Ltd. | EARLY_Phase 1 |
| Recruiting | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid NCT06612840 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid NCT06631079 | NEC Bio B.V | Phase 1 / Phase 2 |
| Recruiting | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity o NCT06616766 | Yuhan Corporation | Phase 1 / Phase 2 |
| Not Yet Recruiting | HS-IT201 Injection in the Treatment of Advanced Solid Tumors NCT06613152 | Qingdao Sino-Cell Biomedicine Co., Ltd. | EARLY_Phase 1 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMP NCT06956248 | National Cancer Centre, Singapore | — |
| Recruiting | A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid T NCT06150885 | Ever Supreme Bio Technology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid NCT06493864 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and O NCT06503783 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer NCT06429891 | Hua Zhu | N/A |
| Terminated | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors NCT06198426 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 / Phase 2 |
| Recruiting | Genetically Modified T Cells Treating Malignant Tumors NCT06515626 | Yi Zhang | EARLY_Phase 1 |
| Recruiting | To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer NCT06504732 | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 2 / Phase 3 |
| Recruiting | SMP-3124LP in Adults With Advanced Solid Tumors NCT06526819 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Recruiting | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib NCT06401356 | Novartis Pharmaceuticals | Phase 3 |
| Not Yet Recruiting | A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tu NCT06537505 | Beidahuang Industry Group General Hospital | Phase 2 |
| Recruiting | Study of STP938 in Advanced Solid Tumours NCT06297525 | Step Pharma, SAS | Phase 1 |
| Not Yet Recruiting | Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Maligna NCT06528249 | Zhejiang Provincial People's Hospital | Phase 1 |
| Not Yet Recruiting | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors NCT06531486 | NovaOnco Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointes NCT06500052 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Soli NCT06440005 | Angiex, Inc. | Phase 1 |
| Recruiting | A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors NCT06475131 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors NCT06487858 | BeOne Medicines | Phase 1 |
| Recruiting | Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan NCT06443307 | Peking University | — |
| Withdrawn | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer NCT06416436 | University of Kansas Medical Center | Phase 1 |
| Recruiting | Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients NCT06212076 | Nanjing Immunophage Biotech Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors NCT06046742 | Guangzhou Virotech Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other S NCT06469008 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors NCT06452160 | BridGene Biosciences Inc. | Phase 1 |
| Recruiting | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lu NCT06475300 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting NCT07019194 | Impact Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors NCT06368921 | Guangzhou Virotech Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors NCT06468358 | L & L Bio Co., Ltd., Ningbo, China | Phase 1 / Phase 2 |
| Recruiting | A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors NCT06190886 | Proviva Therapeutics, Inc. | Phase 1 |
| Terminated | A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors NCT06336148 | Actym Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of GC203 TIL in Advanced Malignant Solid Tumors NCT06375187 | Shanghai Juncell Therapeutics | Phase 1 |
| Recruiting | Intratumoral CAN2109 in Subjects With Solid Tumors NCT06332430 | Canwell Biotech Limited | Phase 1 |
| Terminated | A Study of ASP1012 in Adults With Solid Tumors NCT06171178 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers NCT06443710 | Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd. | Phase 1 |
| Recruiting | A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor NCT06239298 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors NCT06425926 | Georgiamune Inc | Phase 1 / Phase 2 |
| Enrolling By Invitation | A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors NCT06215846 | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Phase 1 |
| Completed | Online Proton Adaptive Radiotherapy NCT06310655 | Washington University School of Medicine | N/A |
| Unknown | Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors NCT05322512 | Peking University Cancer Hospital & Institute | N/A |
| Recruiting | A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors NCT06403735 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors NCT06384807 | Biohaven Therapeutics Ltd. | Phase 1 / Phase 2 |
| Recruiting | Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors NCT06349837 | Sichuan University | Phase 1 |
| Active Not Recruiting | A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors NCT06364696 | Astellas Pharma Inc | Phase 1 |
| Recruiting | A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors NCT06394622 | Fudan University | Phase 1 |
| Recruiting | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours NCT06305247 | Ipsen | Phase 1 / Phase 2 |
| Recruiting | PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors NCT06383598 | Hua Zhu | N/A |
| Completed | Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors NCT06592092 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Terminated | Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications NCT06299761 | Boundless Bio, Inc. | Phase 1 |
| Active Not Recruiting | Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) NCT06308263 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
| Recruiting | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors NCT06259552 | SparX Biotech(Jiangsu) Co., Ltd. | Phase 1 |
| Completed | A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors NCT05991349 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 / Phase 2 |
| Terminated | Study of 23ME-01473 in Patients With Advanced Solid Malignancies NCT06290388 | 23andMe, Inc. | Phase 1 / Phase 2 |
| Recruiting | An Exploratory Study by Fast CAR T Cells NCT06327997 | Shanghai Cell Therapy Group Co.,Ltd | EARLY_Phase 1 |
| Active Not Recruiting | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Meta NCT06105021 | Affini-T Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Ac NCT06234098 | Alyssum Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumor NCT06234423 | OnCusp Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor NCT06245018 | Nuwacell Biotechnologies Co., Ltd. | N/A |
| Recruiting | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors NCT06171750 | Ankyra Therapeutics, Inc | Phase 1 |
| Recruiting | HS-IT101 Injection in the Treatment of Advanced Solid Tumors NCT06342336 | Qingdao Sino-Cell Biomedicine Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid NCT06101082 | China Medical University, China | Phase 1 |
| Terminated | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation NCT06005974 | Recursion Pharmaceuticals Inc. | Phase 2 |
| Recruiting | A Study of AK131 in Patients With Advanced Solid Tumors NCT06166888 | Akeso | Phase 1 |
| Terminated | ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer NCT06465017 | The First Affiliated Hospital of Xiamen University | N/A |
| Withdrawn | Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors NCT05284214 | Partner Therapeutics, Inc. | Phase 2 |
| Suspended | oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection NCT05938296 | Binhui Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma a NCT05965856 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer NCT06184035 | Spago Nanomedical AB | Phase 1 / Phase 2 |
| Recruiting | Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid T NCT06132828 | Zhejiang Doer Biologics Co., Ltd. | Phase 1 |
| Recruiting | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alteratio NCT06160752 | Tyra Biosciences, Inc | Phase 1 |
| Not Yet Recruiting | NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor NCT06134960 | Peking University | Phase 1 |
| Recruiting | A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors NCT05923008 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 / Phase 2 |
| Completed | Phase I Clinical Trial of 68Ga-NOTA-SNA002 NCT05989997 | SmartNuclide Biopharma | Phase 1 |
| Recruiting | Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors NCT06086522 | Qualigen Theraputics, Inc. | Phase 1 |
| Recruiting | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tum NCT06008288 | Allist Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemother NCT06106360 | Inova Health Care Services | — |
| Not Yet Recruiting | The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tum NCT06112041 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Unknown | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent NCT06075849 | Panolos Bioscience | Phase 1 |
| Recruiting | Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors NCT05645523 | St. Jude Children's Research Hospital | EARLY_Phase 1 |
| Recruiting | A Study of Avutometinib for People With Solid Tumor Cancers NCT06104488 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Registry Study in MSI/dMMR Solid Tumors NCT06004713 | Peking University Cancer Hospital & Institute | — |
| Completed | ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors NCT06188468 | The First Affiliated Hospital of Xiamen University | N/A |
| Unknown | A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors NCT06041035 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors NCT06241898 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Phase 1 |
| Recruiting | Tumor Vaccines for Solid Tumors NCT06102837 | Huashan Hospital | — |
| Completed | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK NCT06036836 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid NCT05981703 | BeOne Medicines | Phase 1 |
| Recruiting | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Thera NCT05989724 | Qurgen Inc. | Phase 1 |
| Recruiting | A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or M NCT06016062 | RemeGen Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors NCT07382531 | Binhui Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors NCT06014502 | ImmunoGenesis | Phase 1 |
| Completed | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractor NCT05990920 | NKGen Biotech, Inc. | Phase 1 |
| Terminated | BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors NCT05935098 | BeiGene | Phase 1 |
| Recruiting | A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors NCT06209385 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Unknown | A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours NCT06237413 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Unknown | A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastat NCT05798026 | Eutilex | Phase 1 |
| Unknown | Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery NCT06015269 | Shanghai Cell Therapy Group Co.,Ltd | Phase 1 |
| Not Yet Recruiting | A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors NCT05971589 | Suzhou BlueHorse Therapeutics Co., Ltd. | EARLY_Phase 1 |
| Not Yet Recruiting | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Soli NCT05361954 | Sorrento Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | A Clinical Study on TILs for the Treatment of Advanced Solid Tumors NCT05971576 | Suzhou BlueHorse Therapeutics Co., Ltd. | EARLY_Phase 1 |
| Recruiting | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors NCT05985161 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | JYB1907 in Subjects With Advanced Solid Tumors NCT05821595 | Jemincare | Phase 1 |
| Unknown | Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma NCT04977167 | HitGen Inc. | Phase 1 |
| Not Yet Recruiting | A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors NCT05940116 | Hansoh BioMedical R&D Company | Phase 1 |
| Active Not Recruiting | Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors NCT06220318 | Fujian Haixi Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors NCT05828459 | Onward Therapeutics | Phase 1 |
| Recruiting | RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression NCT05940896 | RemeGen Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tum NCT05627063 | Abbisko Therapeutics Co, Ltd | Phase 1 |
| Recruiting | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Ma NCT05803018 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanc NCT05672459 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | The ACC Preclinical Research Platform for Precision Oncology NCT06339541 | Fondazione del Piemonte per l'Oncologia | — |
| Recruiting | Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001 NCT06410092 | Sound Biopharmaceuticals Ltd. | Phase 1 |
| Unknown | Neoantigen Derived DCs as Cancer Treatment NCT05767684 | National Health Research Institutes, Taiwan | Phase 1 |
| Recruiting | An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells NCT06249256 | Shanghai Cell Therapy Group Co.,Ltd | EARLY_Phase 1 |
| Recruiting | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Seque NCT06028724 | Centro di Riferimento Oncologico - Aviano | — |
| Recruiting | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors NCT05907980 | Chugai Pharmaceutical | Phase 1 |
| Recruiting | FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 | Parabilis Medicines, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of PYX-106 in Solid Tumors NCT05718557 | Pyxis Oncology, Inc | Phase 1 |
| Recruiting | Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Sol NCT05831033 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Unknown | A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors NCT05941936 | Suzhou BlueHorse Therapeutics Co., Ltd. | EARLY_Phase 1 |
| Recruiting | Study of PAT in Patients With Solid Tumor Cancers NCT05338658 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Active Not Recruiting | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer NCT05678010 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors NCT05869240 | Betta Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of GS-4528 in Adults With Solid Tumors NCT05840224 | Gilead Sciences | Phase 1 |
| Recruiting | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | ECP-1014 Treatment for Patients With Solid Tumor Cancers NCT04930354 | Euclises Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Clinical Study on Intraluminal Injection of FOLactis NCT06512896 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Unknown | Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors NCT06022289 | Tianjin Medical University Second Hospital | Phase 2 |
| Terminated | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer NCT05708924 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors NCT05736731 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Unknown | A Study of BPI-452080 in Subjects With Solid Tumors NCT05843305 | Betta Pharmaceuticals Co., Ltd. | Phase 1 |
| Completed | Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer NCT05943041 | GILongevity | Phase 1 |
| Recruiting | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary S NCT05785039 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors NCT04796012 | University of Texas Southwestern Medical Center | Phase 1 / Phase 2 |
| Recruiting | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 | Institut de Recherches Internationales Servier | Phase 1 / Phase 2 |
| Completed | A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors NCT05735366 | Chugai Pharmaceutical | Phase 1 |
| Recruiting | Characterizing Sleep Among Long-term Survivors of Childhood Cancer NCT05480904 | St. Jude Children's Research Hospital | — |
| Unknown | HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors NCT05895370 | BGI, China | Phase 1 |
| Recruiting | NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors NCT05661201 | Georgetown University | Phase 1 |
| Active Not Recruiting | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors NCT05704985 | DEKA Biosciences | Phase 1 |
| Unknown | HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors NCT05360368 | Shanghai Henlius Biotech | Phase 1 |
| Active Not Recruiting | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically NCT05826600 | iOmx Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced C NCT05735080 | Incyclix Bio | Phase 1 / Phase 2 |
| Unknown | What Unmet Need for the Patients?A Focus on the Social Determinants of Health in Phase 1 Clinical Trials NCT06326242 | European Institute of Oncology | — |
| Recruiting | A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors NCT05749432 | Ganzhou Hemay Pharmaceutical Co., Ltd | Phase 1 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients NCT06010342 | Teligene US | Phase 2 |
| Not Yet Recruiting | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma NCT05095441 | ImmVira Pharma Co. Ltd | Phase 1 |
| Recruiting | A Study of PYX-201 in Advanced Solid Tumors NCT05720117 | Pyxis Oncology, Inc | Phase 1 |
| Recruiting | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688 | TiumBio Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Soli NCT06145802 | Grit Biotechnology | N/A |
| Unknown | Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule NCT05716919 | Machaon Biotherapeutics, Inc. | Phase 1 |
| Terminated | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR4 NCT04242147 | Kadmon, a Sanofi Company | Phase 1 |
| Terminated | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation NCT05737706 | Mirati Therapeutics Inc. | Phase 1 |
| Unknown | A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (V NCT05708950 | Kineta Inc. | Phase 1 / Phase 2 |
| Unknown | UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid T NCT05775666 | Peking University | Phase 1 |
| Unknown | A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors NCT05940181 | jianming xu | N/A |
| Recruiting | APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid NCT05701306 | Ascentage Pharma Group Inc. | Phase 1 |
| Recruiting | Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors NCT06094426 | Grit Biotechnology | EARLY_Phase 1 |
| Active Not Recruiting | A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours NCT05717348 | Elpiscience (Suzhou) Biopharma, Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Ad NCT05076552 | Tachyon Therapeutics, Inc. | Phase 1 |
| Recruiting | PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Recruiting | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA NCT06307249 | Lebanese University | Phase 1 |
| Recruiting | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI NCT05381038 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Recruiting | Autologous Tumour Vaccine Trial NCT05807035 | Vaxine Pty Ltd | Phase 1 |
| Unknown | A Study of RD14-01 in Patients With Advanced Solid Tumors NCT05748938 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 / Phase 2 |
| Recruiting | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib NCT05512208 | University of Oklahoma | Phase 2 |
| Unknown | Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecolo NCT05724732 | RenJi Hospital | EARLY_Phase 1 |
| Recruiting | Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors NCT05544240 | Williams Cancer Foundation | Phase 1 |
| Unknown | A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Sol NCT05745454 | su haichuan | N/A |
| Recruiting | Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Se NCT05585684 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | — |
| Active Not Recruiting | SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors NCT05642780 | Klus Pharma Inc. | Phase 2 |
| Recruiting | Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignanc NCT05707325 | Westlake Therapeutics | EARLY_Phase 1 |
| Completed | Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer NCT05702424 | IGM Biosciences, Inc. | Phase 1 |
| Unknown | Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) NCT05798533 | BGI, China | Phase 1 |
| Active Not Recruiting | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors NCT05653882 | Asher Biotherapeutics, Inc. | Phase 1 |
| Unknown | Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy NCT05828238 | Affiliated Hospital of Jiangnan University | EARLY_Phase 1 |
| Recruiting | Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tu NCT06248697 | Shanghai Cell Therapy Group Co.,Ltd | EARLY_Phase 1 |
| Unknown | ALG.APV-527 First-in-human Study NCT05934539 | Aptevo Therapeutics | Phase 1 / Phase 2 |
| Completed | Study on the Safety and Effectiveness of Varian ProBeam Proton Therapy Equipment in the Treatment of Solid Tum NCT05914142 | Guangzhou Concord Cancer Center | N/A |
| Unknown | TIL Cells for the Treatment of the Advanced Solid Tumors Patients NCT05649618 | Fujian Cancer Hospital | EARLY_Phase 1 |
| Terminated | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway NCT05578092 | Mirati Therapeutics Inc. | Phase 1 |
| Unknown | Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors NCT06022276 | Tianjin Medical University Second Hospital | N/A |
| Unknown | A Study of RD14-01 in Patients With Advanced Solid Tumors NCT05638828 | Shen Lin | EARLY_Phase 1 |
| Enrolling By Invitation | A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Pe NCT05741242 | Jaime Leandro Foundation for Therapeutic Cancer Vaccines | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With A NCT05707676 | L & L Bio Co., Ltd., Ningbo, China | Phase 1 |
| Recruiting | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced So NCT05584670 | Sanofi | Phase 1 / Phase 2 |
| Terminated | Oral AMXT 1501 Dicaprate in Combination With IV DFMO NCT05500508 | Aminex Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Impact of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Ad NCT05858424 | Centre Leon Berard | N/A |
| Active Not Recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors NCT05544552 | Tyra Biosciences, Inc | Phase 1 / Phase 2 |
| Recruiting | A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors NCT06117566 | Shanghai Jiatan Pharmatech Co., Ltd | Phase 1 / Phase 2 |
| Terminated | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Tr NCT05581719 | Enlivex Therapeutics RDO Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Mal NCT05266612 | Virogin Biotech Canada Ltd | Phase 1 |
| Recruiting | Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors NCT05909436 | Guangzhou Gloria Biosciences Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With NCT05375084 | Navire Pharma Inc., a BridgeBio company | Phase 1 |
| Unknown | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation NCT05528406 | Shanghai Henlius Biotech | Phase 2 |
| Unknown | [68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors NCT05490264 | SmartNuclide Biopharma | EARLY_Phase 1 |
| Recruiting | SB17170 Phase 1 Clinical Trial in Solid Tumors NCT05522868 | SPARK Biopharma | Phase 1 |